EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Semaglutide Selectively Improves Metabolic and Cognitive Function in 5xFAD Mice

Lucy Shahabian iD, Demos Kynigopoulos iD, Revekka Papacharalambous, Eleni Ioannou, Sofia Dionysiou iD, Sylia Christou iD, Michalis Picolos iD, Menelaos Pipis, Elena Panayiotou

International Journal of Molecular Sciences · 11.06.2026 · 27 (12) · 5311

DOI: 10.3390/ijms27125311 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.06.2026. Verfasst von Lucy Shahabian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Neuropathology Department, Cyprus Institute of Neurology and Genetics, 2371 Nicosia, Cyprus. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognition, Glucagon-Like Peptides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cyprus Institute of Neurology and Genetics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) and metabolic syndrome often occur together, sharing characteristics such as insulin resistance, dyslipidemia, and chronic inflammation. Metabolic dysfunction frequently precedes cognitive decline, indicating that early intervention might alter the disease’s progression. We investigated whether the GLP-1 receptor agonist semaglutide (SMGL) influences metabolic impairment and AD pathology in an AD mouse model. Male and female 5xFAD and wild-type (WT) mice on regular (RD) or high-fat diets (HFD) were administered SMGL for 13 weeks. SMGL-treated groups exhibited significant, context-dependent effects. In metabolically challenged 5xFAD HFD mice, treatment led to reduced body weight, improved glucose tolerance, normalized cholesterol levels, and a restored balance of adiponectin and leptin. These improvements were associated with reduced Aβ40 and Aβ42 levels, restored GLP-1 receptor expression, increased synaptophysin and βIII-tubulin levels, and enhanced spatial memory. SMGL also decreased Iba1 and CD68 immunoreactivity in the hippocampus and cortex, reduced macrophage infiltration, and lowered CD36 expression in visceral adipose tissue (VAT), indicating coordinated anti-inflammatory effects. WT RD mice showed minimal metabolic responses and a modest decline in Y-maze performance, suggesting that excessive GLP-1 receptor activation may disrupt neuronal homeostasis when metabolic status is normal. SMGL acts as a context-specific metabolic and neuroprotective agent, offering the greatest benefits under conditions of metabolic dysfunction. These findings in a preclinical model suggest that targeting early metabolic disturbances provides a testable hypothesis for attenuating AD-related neurodegeneration, though further translational studies are required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCognitionGlucagon-Like PeptidesAnimalsSemaglutideMiceMaleFemaleDisease Models, AnimalMice, TransgenicDiet, High-FatAmyloid beta-PeptidesAdiponectinGlucagon-Like Peptide-1 ReceptorHippocampusBody Weight

Stichwörter der Autor:innen

5xFAD mouse modelAlzheimer’s diseaseadipose–brain axisinsulin resistancemetabolic syndromeneuroinflammation

Substanzen

SemaglutideGlucagon-Like PeptidesAmyloid beta-PeptidesAdiponectinGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • Neuropathology Department, Cyprus Institute of Neurology and Genetics, 2371 Nicosia, Cyprus.
  • Cyprus Institute of Neurology and Genetics School, 2371 Nicosia, Cyprus.
  • Alithias Endocrinology Centre, 2324 Nicosia, Cyprus.

ORCID-Profile: Lucy Shahabian, Demos Kynigopoulos, Sofia Dionysiou, Sylia Christou, Michalis Picolos

Förderung

  • Cyprus Institute of Neurology and Genetics

Zitieren

APA

Shahabian, L., Kynigopoulos, D., Papacharalambous, R., Ioannou, E., Dionysiou, S., Christou, S., Picolos, M., Pipis, M., & Panayiotou, E. (2026). Semaglutide Selectively Improves Metabolic and Cognitive Function in 5xFAD Mice. International Journal of Molecular Sciences, 27(12), 5311. https://doi.org/10.3390/ijms27125311

Vancouver

Shahabian L, Kynigopoulos D, Papacharalambous R, Ioannou E, Dionysiou S, Christou S, et al. Semaglutide Selectively Improves Metabolic and Cognitive Function in 5xFAD Mice. International Journal of Molecular Sciences. 2026;27(12):5311. doi:10.3390/ijms27125311

BibTeX
@article{Shahabian2026,
  author = {Shahabian, Lucy and Kynigopoulos, Demos and Papacharalambous, Revekka and Ioannou, Eleni and Dionysiou, Sofia and Christou, Sylia and Picolos, Michalis and Pipis, Menelaos and Panayiotou, Elena},
  title = {Semaglutide Selectively Improves Metabolic and Cognitive Function in 5xFAD Mice},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {12},
  pages = {5311},
  doi = {10.3390/ijms27125311}
}
Kostenlos starten →